Deadline Alert: Fulgent Genetics, Inc. (FLGT) - Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Class Action Deadlines and Encourages Shareholders to Contact the Firm and Actively Participate

NEW YORK--(BUSINESS WIRE)--Nov 15, 2022--

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Fulgent securities between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/flgt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (2) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (3) Fulgent’s revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (4) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.